Stock Ratings / Health Care / BCAX / earnings

OLMA (31) ABUS (18) LXRX (27) IMMX (29) ⌘ Pro Terminal →

Bicara Therapeutics Inc. (BCAX) Next Earnings Date & Expected ±12.5% Move

Q: When is BCAX's next earnings date?

Based on SEC filing cadence, Bicara Therapeutics Inc. (BCAX)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is BCAX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for BCAX, spanning a range between $8.51 and $10.95.

$9.73 -0.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.71

Bicara Therapeutics Inc. (BCAX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $643.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BCAX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $9.73 (-0.31% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #842 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BCAX compare to OLMA and ABUS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BCAX?

▼

Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.71 (-0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCAX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY BCAX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$17.33+0.8% Next Q

Q2 (-2Q)

Grade E$17.47-3.3% Next Q

Q3 (-1Q)

Grade E$16.89-42.4% Next Q

Current

Grade E$9.73-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BCAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BCAX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.46) and Max Pain ($10.22) forces dealer call-delta covering toward $32.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BCAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.22 Expected Swing

MODEL EARNINGS SETUP GAUGE

BCAX Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$137.9M	-$107.1M	52%
FY 2024	2024-12-31	$0	-$68.0M	-$74.8M	52%
FY 2023	2023-12-31	$0	-$52.0M	-$45.6M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCAX)

✓Walkthrough of BCAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BCAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.17%▼ SUPPORT BREAKDOWN

2026-11-02O $9.76H $9.76L $9.73C $9.73VOL 3.20M

RES: $17.30SUP: $12.97SMA50: $19.46SMA200: $21.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCAX Butterfly Map → + Track BCAX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BCAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BCAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCAX)

Health Care Rank #842 of 1016 ⚔️ OLMA vs BCAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCAX vs. OLMA, ABUS, LXRX, IMMX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bicara Therapeutics Inc. (BCAX) ranks #842 by composite RQD confidence (30/100, grade E) and #413 by equity capitalization ($643.9M). Within this direct 5-issuer industry benchmark cohort, BCAX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. OLMA currently holds the highest overall quantitative score in the immediate peer group at 31/100 (E) compared with BCAX at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BCAX ACTIVE Bicara Therapeutics Inc.	E	30/100	—	—	-35.0%	-0.31%	$643.9M	Benchmark Subject
OLMA Olema Pharmaceuticals Inc.	E	31/100	—	—	-32.8%	-2.14%	$641.4M	/olma-vs-bcax →
ABUS Arbutus Biopharma Corporation	E	18/100	—	—	-35.0%	-0.93%	$656.0M	/abus-vs-bcax →
LXRX Lexicon Pharmaceuticals Inc.	E	27/100	—	96.0%	-31.5%	-0.34%	$658.5M	/lxrx-vs-bcax →
IMMX Immix Biopharma Inc.	E	29/100	—	—	-35.0%	-1.78%	$661.6M	/immx-vs-bcax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023658

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicara Therapeutics Inc. (BCAX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$137.9M, operating cash flow of -$106.8M, and free cash flow of -$107.1M (-43.2% YoY). On the balance sheet, BCAX closed FY2025 with $431.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$137.9M	-$106.8M	-$107.1M	$431.0M	—
FY2024 (FY)	2024-12-31	$0	-$68.0M	-$74.8M	-$74.8M	$510.0M	—
FY2023 (FY)	2023-12-31	$0	-$52.0M	-$45.6M	-$45.6M	—	—

3. BCAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BCAX compare to OLMA and ABUS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BCAX?

Where is BCAX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCAX last traded at $9.73 (-0.31% on volume of 3,197,807 shares), positioning the stock -50.00% below its 50-day simple moving average ($19.46) and -54.04% below its 200-day simple moving average ($21.17). Across its 52-week range of $8.36 to $30.99, BCAX sits at the 6.1% percentile with a 14-day RSI of 21.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.51 to $10.95).